BioStock: Xintela reports promising results in Covid-19 project
During the autumn, Xintela has investigated whether the company’s selected stem cells, XSTEM, can be used for the treatment of Acute Respiratory Distress Syndrome (ARDS), a life-threatening lung complication that affects some Covid-19 patients. The company has completed the majority of the preclinical study, and so far, it has given promising results. They have seen a clear improvement in lung function after the XSTEM treatment and a reversal of the critical ARDS condition – something that is very difficult to achieve with current treatments.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se